Search

Zentalis Pharmaceuticals Inc

Chiusa

4.92 1.23

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.76

Massimo

4.93

Metriche Chiave

By Trading Economics

Entrata

-136K

-35M

EPS

-0.503

Dipendenti

106

EBITDA

2.2M

-35M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+49.39% upside

Dividendi

By Acuity

Utili prossimi

11 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

36M

331M

Apertura precedente

3.69

Chiusura precedente

4.92

Zentalis Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 ago 2026, 23:56 UTC

Baidu Inc. shares are roughly flat in after-market trading, remaining near unchanged since Tuesday's close and positioned around the midpoint of its one-month range.

4 ago 2026, 23:56 UTC

Ziff Davis Inc shares are lower during after-market hours, with no specific news identified to explain the movement. The stock fluctuated earlier in the session.

4 ago 2026, 23:56 UTC

Centene Corp shares are higher in after-market hours, continuing a recent upward trend amid positive market sentiment following a narrowing U.S. trade deficit.

4 ago 2026, 23:56 UTC

Insulet Corp shares are lower in after-market hours, showing little change since Tuesday's close amid a lack of specific company news.

4 ago 2026, 23:56 UTC

Coherus BioSciences Inc shares are higher in after-market hours, reflecting strong demand since Tuesday's close amid a narrowing U.S. trade deficit.

4 ago 2026, 23:56 UTC

Xcel Energy shares advanced in after-market trading, reaching a high of 0.60% above Tuesday's close, though still below the 20-day moving average.

4 ago 2026, 23:56 UTC

Nasdaq Inc. shares showed routine trading activity during after-market hours, remaining roughly flat since Tuesday's close and positioned above its 20-day moving average.

4 ago 2026, 23:56 UTC

Correlated Moves
ETF Constituents
Macro News

The iShares U.S. Aerospace & Defense ETF is trading higher in after-market hours, supported by positive earnings from technology stocks and geopolitical developments.

4 ago 2026, 23:56 UTC

Darling Ingredients Inc shares are higher in after-market trading, rebounding from earlier session lows. No specific news was identified to explain the movement.

4 ago 2026, 23:56 UTC

ETF Constituents

The Consumer Staples Select Sector SPDR Fund traded near unchanged in after-market hours, supported by positive contributions from Walmart, Costco, and PepsiCo.

4 ago 2026, 23:56 UTC

Public Service Enterprise Group Inc shares are modestly higher in after-market hours. No specific company news was identified to explain the movement.

4 ago 2026, 23:56 UTC

TE Connectivity Ltd. shares are lower in after-market trading, retracing from earlier gains. The stock remains above its 20-day moving average.

4 ago 2026, 23:56 UTC

Correlated Moves

Skyworks Solutions Inc shares declined in after-market trading, moving lower since Tuesday's close. The stock remains above its 20-day moving average.

4 ago 2026, 23:56 UTC

TAL Education Group shares are higher in after-market hours, recovering slightly after three consecutive sessions of decline and remaining above the 20-day moving average.

4 ago 2026, 23:56 UTC

Packaging Corp of America shares were roughly flat in after-market hours, remaining above their 20-day moving average following three consecutive higher sessions.

4 ago 2026, 23:56 UTC

Regions Financial Corp shares are higher in after-market hours, continuing a trend of strength following four consecutive sessions of gains.

4 ago 2026, 23:56 UTC

Fuelcell Energy Inc shares are lower in after-market trading, with no specific company news identified to explain the decline following Tuesday's close.

4 ago 2026, 23:56 UTC

MACOM Technology Solutions Holdings Inc. shares are lower in after-market trading, reflecting routine fluctuations and positioning below the 20-day moving average.

4 ago 2026, 23:56 UTC

News

Starbucks Corp raised its full-year EPS guidance to approximately $2.60, reflecting strong U.S. same-store sales growth. Shares are gaining in after-market trading.

4 ago 2026, 23:56 UTC

MKS Instruments Inc shares are lower in after-market hours, reflecting notable weakness as they remain significantly below their 20-day moving average.

4 ago 2026, 23:56 UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

4 ago 2026, 23:56 UTC

News

Alphabet Inc's market valuation is approximately $4.6 trillion, bolstered by strong second-quarter results. Shares traded higher in after-market hours, reflecting positive sentiment.

4 ago 2026, 23:56 UTC

The US 10Y Treasury Bond Index is trading roughly flat. The U.S. trade deficit narrowed to $73.3 billion in June from $77.6 billion in May.

4 ago 2026, 23:56 UTC

Whirlpool Corp shares are trading lower in after-market hours, with no specific news identified to explain the movement. They remain near the upper end of their one-month range.

4 ago 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, following a volatile session with no specific news identified to explain the movement.

4 ago 2026, 23:56 UTC

News

Ameresco Inc reported second-quarter revenue of $515.5 million, a 9% increase year-over-year. Shares are trading higher in after-market hours following the results.

4 ago 2026, 23:56 UTC

News

Advanced Energy Industries reported record Q2 revenue of $574.1 million, leading to shares trading higher in after-market hours.

4 ago 2026, 23:56 UTC

Ultra Clean Holdings Inc. shares are higher in after-market trading, despite no specific company news identified. The broader market reflects a narrowing U.S. trade deficit.

4 ago 2026, 23:52 UTC

Correlated Moves

Teradyne Inc. shares gained in after-market trading, reflecting positive sentiment in U.S. markets amid easing inflation concerns related to oil supply negotiations.

4 ago 2026, 23:52 UTC

Brazil's upcoming inflation report on August 11, 2026, is poised to influence central bank policy amid rising energy prices and declining manufacturing activity.

Confronto tra pari

Modifica del prezzo

Zentalis Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

49.39% in crescita

Previsioni per 12 mesi

Media 7.29 USD  49.39%

Alto 11 USD

Basso 4 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zentalis Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

8 ratings

5

Acquista

3

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat